Novartis (NYSE:NVS) is reportedly backing off a 2016 start date to test its autofocusing contact lens in clinical trials, but it told Reuters that the product is “progressing steadily” in its collaboration with Google (NSDQ:GOOGL).
In 2014, CEO Joe Jimenez said he hoped the lens would be on the market in 5 years and last year he said his company’s Alcon eye care unit was on track to begin clinical testing in 2016.
Get the full story at our sister site, Drug Delivery Business News.